SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Smith Micro entered into inducement letter agreements to issue 487,349 unregistered Common Stock warrants at an exercise price of $3.80 per share in exchange for warrant holders exercising existing warrants at $3.35 per share, raising approximately $1.6 million in gross proceeds under Section 4(a)(2) and Rule 506 exemptions.
View raw filing on EDGAR →Capstone entered into an Amended and Restated Common Stock Purchase Agreement on June 11, 2026, establishing an equity line of credit permitting the sale of up to $20,000,000 in newly issued common stock to an accredited investor at 97% of VWAP, with up to 4,975,197 registered shares potentially dilutive to existing shareholders.
View raw filing on EDGAR →The disclosure centers on a material change to Ms. Conn's compensation arrangement as CFO: her transition to part-time status effective June 29, 2026, with a corresponding salary adjustment to reflect her reduced work schedule. While the filing is captioned Item 5.02 (which covers departures, appointments, and compensation), the principal action disclosed is a compensatory arrangement modification rather than a departure (she remains CFO) or appointment (no new officer is being named). The salary adjustment tied to the role change is the material event.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 Annual Meeting of Stockholders. The filing reports the vote tallies for two proposals: election of seven directors and ratification of Deloitte & Touche LLP as independent auditor. All director nominees were duly elected, and the auditor appointment was ratified. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms the composition of the board and auditor for the fiscal year.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Generac's 2026 annual meeting, covering three proposals: election of directors (Marcia J. Avedon, Bennett J. Morgan, Dominick P. Zarcone), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. The tabulated voting results with For/Against/Abstain/Broker Non-Vote columns are the hallmark of Item 5.07 disclosure and are material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of TG Therapeutics' 2026 Annual Meeting held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The disclosure is material as it documents shareholder approval of board composition and auditor ratification, though notably Proposal 3 (say-on-pay) was not approved, with 48.9 million votes against versus 31.9 million for.
View raw filing on EDGAR →The filing discloses termination of an Equity Distribution Agreement (Sales Agreement) dated July 28, 2023, which provided for up to $450 million in aggregate gross sales of common stock through sales agents and forward sellers. While the termination itself is routine (triggered by expiration of the underlying shelf registration), the agreement's material size and the company's loss of this financing flexibility warrant disclosure. The termination is not a covenant breach, M&A activity, or other more specific event type, making "other_material" the most appropriate classification.
View raw filing on EDGAR →Genprex received a formal delisting notice from Nasdaq on June 10, 2026, for failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for a compliance period due to a reverse stock split effected on October 21, 2025, and must request a hearing before a Nasdaq Hearings Panel to avoid delisting.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the certified results of Everpure's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for three proposals: election of three Class II directors (Andrew Brown, John Colgrove, and Roxanne Taylor), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses a change in the Company's independent registered public accounting firm: Stephano Slack LLC was dismissed effective June 12, 2026, and replaced by Sadler, Gibb & Associates, LLC on the same date. While the prior auditor's report contained an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern, the primary event disclosed under Item 4.01 is the auditor change itself. This is material as it affects investor confidence in financial reporting and audit quality.
View raw filing on EDGAR →DATZ World Holdings Corp. completed a material merger on June 8, 2026, acquiring RagingBull.com, LLC through a subsidiary merger in exchange for 15,000,000 newly issued shares, resulting in a change of control with RagingBull Holders obtaining approximately 95% beneficial ownership post-merger, a corporate name change, and a reverse stock split.
View raw filing on EDGAR →The registrant issued 15,000,000 unregistered shares of Common Stock to RagingBull Holders in connection with the merger, relying on Section 4(2) and Rule 506 exemptions, materially diluting existing shareholder equity and voting power.
View raw filing on EDGAR →Item 5.02 incorporates Item 1.01 by reference, indicating material changes to executive roles, compensation, or governance in connection with the merger and change of control, though the specific nature of these changes cannot be determined without access to the full Item 1.01 disclosure.
View raw filing on EDGAR →The Company issued 865,903 unregistered shares of common stock in exchange for Series B Preferred Stock held by Streeterville Capital, LLC pursuant to Section 3(a)(9) exemption. This is a dilutive equity issuance that materially increases the common share count and would affect a reasonable investor's assessment of ownership dilution and voting power, particularly given the substantial number of shares issued relative to a small-cap issuer.
View raw filing on EDGAR →This Item 1.01 discloses a material amendment to an Agreement and Plan of Merger between AI Technology Group Inc., AVM Biotechnology Inc., and Biomed 360 Solutions Corp. The June 4, 2026 amendment modifies critical merger terms including investment obligations (tranches totaling over $50 million), conversion rates for convertible loans, and extends the Closing Date from July 26, 2026 to December 31, 2026. These are substantive changes to a material acquisition transaction that would significantly affect investor assessment of the merger's timing, financing structure, and likelihood of completion.
View raw filing on EDGAR →Edible Garden AG entered into a $12 million debt financing agreement secured by promissory notes with restrictive covenants. The transaction was disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and incorporated by reference in Item 2.03 (Creation of a Direct Financial Obligation).
View raw filing on EDGAR →The filing discloses Item 5.07 results from Research Frontiers' Annual Meeting of Stockholders held June 11, 2026, reporting voting outcomes on four proposals: election of Darryl Daigle to the Board (6,614,329 shares in favor), ratification of CohnReznick LLP as independent accountants (19,445,284 shares in favor), non-binding approval of executive compensation (7,016,800 shares in favor), and frequency of say-on-pay votes (6,575,519 shares favoring annual frequency). This is a standard shareholder vote results disclosure material to investors' understanding of governance and compensation approval.
View raw filing on EDGAR →The filing discloses conversion of approximately $97.5 million in convertible notes into 7,649,523 shares of Class A Ordinary Common Stock on June 11, 2026, pursuant to Item 3.02. The Conversion Shares were issued unregistered under Section 4(a)(2) and Regulation D exemptions, representing a significant dilutive equity issuance that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →Michael Amoroso resigned as a member of the Board of Directors of Abeona Therapeutics Inc. effective immediately on June 11, 2026, and also resigned from the Nominating and Corporate Governance Committee. This is a clear executive departure disclosed under Item 5.02, and board departures are material events affecting the registrant's governance structure and investor assessment.
View raw filing on EDGAR →SharonAI announced a six-year strategic compute collaboration with NVIDIA Corporation under a Master Cloud Services Agreement with a contract value of up to $4.88 billion, dated June 8, 2026. This represents a material commercial arrangement that would substantially affect the registrant's revenue, capital requirements, and operational obligations. The filing extensively discusses performance risks, financing needs, and termination provisions, all hallmarks of a material business engagement requiring disclosure under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →The filing discloses results of two stockholder votes held on June 10, 2026: (1) an annual meeting where stockholders re-elected two directors and approved executive compensation and auditor ratification, and (2) a special meeting where stockholders approved an Investment Advisory Agreement for the Company's transition from internally managed to externally managed structure. The externalization represents a material structural change to the Company's operations, making these vote results material to investors.
View raw filing on EDGAR →The exhibit announces results of an extraordinary general meeting held on June 12, 2026, where shareholders approved two key resolutions: (1) a 35-for-1 share consolidation affecting both Class A and Class B ordinary shares, and (2) amendment and adoption of new memorandum and articles of association to reflect the consolidation. This is a direct disclosure of shareholder vote results on material corporate actions, matching the shareholder_vote_results taxonomy entry.
View raw filing on EDGAR →XCF Global entered into securities purchase agreements to issue 4,000,000 unregistered shares of Class A common stock for $600,000 in gross proceeds ($0.15/share) to accredited investors under Section 4(a)(2) and Regulation D Rule 506(b), with placement agent compensation of 7% cash fee (233,333 shares) plus 3% warrant coverage, creating material dilution to existing shareholders.
View raw filing on EDGAR →The exhibit announces that Cuprina has regained compliance with Nasdaq's minimum bid price requirement after receiving a Staff Delisting Determinations Letter on May 29, 2026, indicating the company's stock had closed below $1.00 for 30 consecutive business days. Although the announcement is positive (regaining compliance), the core disclosure is the resolution of a delisting risk event — the company was previously non-compliant and faced a scheduled hearing before the Nasdaq Hearing Panel on July 7, 2026, which has now been cancelled due to restored compliance. This is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →Eva Live Inc. announced on June 12, 2026, that it "has reached terms for a definitive agreement under which EVA will hold a 51% ownership interest across Spiro Senior Living and related operating entities." This constitutes a material acquisition or change of control transaction—the company is acquiring majority ownership in an operating business. The disclosure of a definitive agreement for a 51% stake in operating entities is a classic M&A event material to investors.
View raw filing on EDGAR →The filing discloses results of an annual stockholder meeting held on June 9, 2026, with detailed voting outcomes on five proposals: election of five directors (Nicolas Cary, Tucker Highfield, Evan Sohn, Manuel Stotz, and Kevin Wilson), ratification of Grassi & Co. as independent auditor, advisory vote on named executive officer compensation, approval of the 2026 Equity Incentive Plan, and approval of an amendment to the 2019 Plan to increase available shares. This is a classic Item 5.07 shareholder vote results disclosure with complete voting tallies and quorum information (74.91% voting power represented).
View raw filing on EDGAR →The filing discloses entry into a material definitive purchase agreement on June 10, 2026, whereby Aspire Biopharma agreed to acquire equity interests and assets of automotive systems businesses from FireFish TopCo, LLC for a purchase price of $30,000,000 plus adjustments. This is a material acquisition transaction disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant business combination that would materially affect the registrant's operations and financial position.
View raw filing on EDGAR →The 6-K discloses entry into Amendment No. 1 to an at-the-market (ATM) sales agreement dated June 11, 2026, which increases the aggregate offering price from $20 million to $60 million—a $40 million increase in authorized equity issuance. This is a material unregistered equity offering under Rule 415, with $9.3 million already sold as of April 1, 2026. The dilutive nature and capital-raising purpose are explicit, making this a dilutive_issuance event material to investors assessing the registrant's capitalization.
View raw filing on EDGAR →Nasdaq imposed a trading halt under Code T12 on June 8, 2026, triggering the board to establish a special committee of independent directors to investigate unusual trading activities. While the company states it is unaware of material undisclosed developments, the trading halt itself and the formal investigation response constitute a material event affecting investor confidence and trading ability. This does not fit neatly into delisting_risk (no notice of delisting), but represents a significant trading disruption warranting disclosure.
View raw filing on EDGAR →Knorex held an Extraordinary General Meeting on 24 June 2026 to vote on the removal of director Wilson Chandra and the appointment of three new directors: Kai Zhong, Lu Liu, and Truong Vinh Phu Le. The meeting notice and proxy card disclose material changes to board composition.
View raw filing on EDGAR →Arrive AI Inc. entered into an Equity Distribution Agreement with Maxim Group LLC on June 11, 2026, to sell up to $14,967,247 of common stock through an "at the market offering" program. This is a classic dilutive equity issuance under Item 1.01, where the company is authorized to raise capital by selling shares at market prices, with Maxim acting as sales agent at a 2.5% commission. The material amount and equity dilution to existing shareholders make this a reportable material event.
View raw filing on EDGAR →Mr. Chay Weei Jye resigned from his position as Co-Chief Executive Officer and as a director of Black Titan Corporation, effective June 12, 2026. The departure of a named executive officer at the C-suite level is a material event that would affect a reasonable investor's assessment of the registrant's leadership and governance.
View raw filing on EDGAR →The filing discloses a registered direct offering of 311,876 common shares and a concurrent private placement of 311,876 warrants (exercisable at $4.008 per share for 5 years) for aggregate gross proceeds of approximately $1.25 million. Item 1.01 describes entry into a securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities. This is a classic dilutive equity issuance combining registered and unregistered securities, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →This 6-K furnishes unaudited condensed consolidated financial statements for the six-month period ended January 31, 2026, together with management's discussion and analysis. The filing explicitly states "On June 12, 2026 the Company announced its unaudited consolidated financial results for the six month period ended January 31, 2026." This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The document includes full financial statements (balance sheet, statements of operations, changes in equity, and cash flows) with accompanying notes, which is characteristic of a periodic filing rather than an event disclosure.
View raw filing on EDGAR →The filing discloses quarterly financial results for the period ended April 30, 2026 via a press release furnished as Exhibit 99.1 under Item 2.02. This is a standard earnings release disclosure, which is material to investors as it provides periodic financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →The filing discloses a special meeting of stockholders held on June 11, 2026, to vote on a merger and spinoff transaction involving Jet.AI, SpinCo, flyExclusive, and FlyX Merger Sub. The core event is the adjournment of the special meeting to June 23, 2026, due to failure to achieve the required majority vote (only 34.2% of shares represented, with ~99% voting in favor but needing majority of all outstanding shares). This is a material acquisition/reorganization activity under Items 1.01 and 2.01, as the transaction involves a merger agreement and spinoff agreement that would result in a change of control and distribution of SpinCo shares to flyExclusive shareholders.
View raw filing on EDGAR →Item 3.01 discloses that OFA Group received notice from Nasdaq on June 9, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has been granted a second 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of Nasdaq listing. This is a material delisting risk event requiring disclosure under Item 3.01.
View raw filing on EDGAR →The filing discloses results of an annual stockholder meeting held June 12, 2026, with voting outcomes on five proposals: election of directors (Keith A. Goldan and Bernhardt G. Zeiher, M.D.), advisory vote on named executive officer compensation, ratification of Deloitte & Touche LLP as auditor, approval of increased equity plan shares (8.4M to 11.5M), and a failed amendment to remove advance notice provisions for director nominations. This is a classic Item 5.07 shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses a Nasdaq deficiency notice under Item 3.01 regarding failure to satisfy the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)). The Company reported negative stockholders' equity of $(12,447,801) as of December 31, 2025, well below the $2,500,000 minimum. While Nasdaq granted an extension through October 12, 2026, the Company faces delisting if it fails to evidence compliance by that deadline or upon filing its 2026 periodic report. This is a material delisting risk event.
View raw filing on EDGAR →Matthew Faber resigned from Tri-County Financial Group's Board of Directors, effective June 11, 2026. The filing discloses a director departure under Item 5.02, with explicit confirmation that the resignation was not due to disagreement with the Company. Board departures are material events affecting the composition of the registrant's governance structure.
View raw filing on EDGAR →The filing discloses announcement of initial cash dividends on the Company's 9.50% Series A Perpetual Preferred Stock via press release under Item 7.01 (Regulation FD Disclosure). While dividend announcements are routine for mature companies, the initiation of dividends on preferred stock—particularly at a 9.50% rate—signals capital structure changes and cash distribution policy that would be material to investors assessing the registrant's financial position and capital allocation strategy. However, the lack of detail in the 8-K body itself (the actual press release is attached as an exhibit) and the use of Item 7.01 (rather than a more specific Item) creates some ambiguity about whether this is a routine preferred dividend announcement or a more significant capital event.
View raw filing on EDGAR →The filing discloses results of an annual stockholder meeting held on June 11, 2026, under Item 5.07. The company reports voting outcomes for three matters: election of six directors (with detailed vote tallies for each nominee), ratification of Eide Bailly LLP as independent auditor, and approval of a certificate amendment to increase authorized common shares to 35,000,000. All three proposals passed with substantial majorities, making this a standard shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses Item 3.01 regarding a Nasdaq compliance notice dated June 12, 2026. While the notice confirms the Company has now achieved compliance with Listing Rule 5250(c)(1) (periodic filing requirement) and closes a prior non-compliance matter from May 21, 2026, the disclosure itself documents a delisting risk event—the Company had previously failed to satisfy a continued listing standard and received a notice of non-compliance. The resolution of this matter is material to investors as it addresses a direct threat to the Company's continued listing on Nasdaq.
View raw filing on EDGAR →The filing discloses results of Neuraxis, Inc.'s annual meeting of stockholders held on June 10, 2026, under Item 5.07. It reports voting outcomes for four matters: election of six directors (all approved with >96% support), ratification of auditor Rosenberg Rich Baker Berman, P.A., amendment to the 2022 Omnibus Securities and Incentive Plan, and approval of the 2025 Employee Stock Purchase Plan. These are routine but material shareholder governance matters.
View raw filing on EDGAR →The filing discloses Board approval of the 2026 Equity Incentive Plan and grants of stock options to named executive officers (Carlos X. Montoya, Ken Park, Brad Hoffman, John Jubilee, and Patrick White) and other employees/service providers. The disclosure details vesting schedules, performance conditions, and exercise prices for equity awards, which constitutes a compensatory arrangement under Item 5.02(e). This is material as it affects executive compensation structure and potential dilution to shareholders.
View raw filing on EDGAR →The filing's primary disclosure is Item 3.01, which reports MicroVision's application to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market due to failure to maintain the $1.00 minimum bid price requirement. The company previously received a deficiency notice in January 2026 and now seeks a transfer to avoid delisting, with an additional 180-calendar-day grace period to regain compliance. This is a material delisting-risk event that would significantly affect investor assessment of the company's exchange status and trading continuity.
View raw filing on EDGAR →Venu Holding Corporation entered into an ATM (at-the-market) Sales Agreement with ThinkEquity LLC on June 12, 2026, authorizing the sale of up to $250 million in common stock shares. This is a dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). ATM offerings are a classic signal of capital raising at small- and mid-cap issuers and would materially affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →Celularity received written notice from Nasdaq on June 9, 2026, that its Market Value of Listed Securities fell below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2). The company has been granted a 180-day compliance period (until December 7, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification. This is a classic delisting risk disclosure under Item 3.01, material to any investor assessing the company's continued public market access.
View raw filing on EDGAR →Item 3.01 discloses that NYSE American's Regulatory Staff determined Perfect Moment Ltd. failed to regain compliance with minimum stockholders' equity requirements by the end of the 18-month compliance period and is "no longer suitable for continued listing." The company's common stock will be suspended from NYSE American during the week of June 15, 2026, and transition to OTC Markets trading. This is a material delisting event that fundamentally affects the registrant's market access and liquidity.
View raw filing on EDGAR →Item 3.02 explicitly discloses an unregistered sale of equity securities (the "Company Shares") issued to Founding Shareholders in a transaction exempt from registration under Section 4(a)(2) and/or Regulation D. The shares are restricted securities under Rule 144. The reference to a Stock Purchase Agreement and the closing of a Purchase Agreement indicates a material equity issuance that would dilute existing shareholders.
View raw filing on EDGAR →